Lexicon Pharma (LXRX) Screens First Patient in Sotagliflozin Phase 3 for Type 1 Diabetes
Tweet Send to a Friend
Lexicon Pharma (NASDAQ: LXRX) announced that it has commenced screening in its first pivotal Phase 3 clinical trial of sotagliflozin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
